R44GM137648

Commercialization of methods and reagents for high-throughput single cell analysis - project summary / abstract

Single-cell RNA sequencing (scRNAseq) provides unprecedented insight into the gene regulatory pathways of living cells in complex tissues. Fluent Biosciences has developed pretemplated instant partitioning for single-cell RNA sequencing (PipSeq) that eliminates the cost and complexity of bespoke microfluidics and instrumentation and features a simple, flexible workflow that can be implemented in any laboratory setting.

With Phase I SBIR support (1 R43 GM137648-01A1), we have demonstrated that PipSeq is intrinsically scalable and is capable of capturing from hundreds to millions of cells in a single reaction. The advent of new, high capacity, and low-cost sequencing modalities such as that developed by Ultima Genomics makes high cell-input single cell transcriptomics not only feasible but practical, enabling previously inaccessible experimental modalities.

In this proposal, we will expand the capabilities of PipSeq single cell analysis to provide simple, scalable, and cost-effective solutions for high cell input applications including deep tissue profiling, multiplexed drug testing, and pooled CRISPR screening.

Fluent Biosciences

THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) SUPPORTS BASIC RESEARCH THAT INCREASES OUR UNDERSTANDING OF BIOLOGICAL PROCESSES AND LAYS THE FOUNDATION FOR ADVANCES IN DISEASE DIAGNOSIS, TREATMENT, AND PREVENTION. NIGMS ALSO SUPPORTS RESEARCH IN SPECIFIC CLINICAL AREAS THAT AFFECT MULTIPLE ORGAN SYSTEMS: ANESTHESIOLOGY AND PERI-OPERATIVE PAIN, CLINICAL PHARMACOLOGY ?COMMON TO MULTIPLE DRUGS AND TREATMENTS, AND INJURY, CRITICAL ILLNESS, SEPSIS, AND WOUND HEALING.? NIGMS-FUNDED SCIENTISTS INVESTIGATE HOW LIVING SYSTEMS WORK AT A RANGE OF LEVELSFROM MOLECULES AND CELLS TO TISSUES AND ORGANSIN RESEARCH ORGANISMS, HUMANS, AND POPULATIONS. ADDITIONALLY, TO ENSURE THE VITALITY AND CONTINUED PRODUCTIVITY OF THE RESEARCH ENTERPRISE, NIGMS PROVIDES LEADERSHIP IN SUPPORTING THE TRAINING OF THE NEXT GENERATION OF SCIENTISTS, ENHANCING THE DIVERSITY OF THE SCIENTIFIC WORKFORCE, AND DEVELOPING RESEARCH CAPACITY THROUGHOUT THE COUNTRY.

93.859 - Biomedical Research and Research Training

National Institute of General Medical Sciences (NIGMS) [HHS - NIH]

Massachusetts United States

State-Wide

PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) (PA-22-176)

Amendment Since initial award the End Date has been shortened from 07/31/25 to 07/10/24 and the total obligations have decreased 16% from $1,146,224 to $965,602.